全球癌症檢測和篩檢市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球癌症檢測和篩檢市場預計將從2025年的2,026.6億美元成長至2034年的3,629.8億美元，2026年至2034年的複合年成長率（CAGR）為6.69%。隨著醫療機構將早期疾病檢測視為改善治療效果和提高患者存活率的優先事項，該市場正經歷強勁成長。癌症檢測和篩檢技術能夠透過影像學、臨床檢測、分子檢測和基因分析及時識別各種癌症。癌症發生率的上升、公眾意識的提高以及政府篩檢計畫的擴大，正在推動先進診斷解決方案的廣泛應用。醫療服務可近性的改善也促進了市場的進一步發展。

分子診斷、液態生物檢體、基因測序和人工智慧成像等領域的技術進步正在改變癌症檢測能力。醫療機構正增加對精準醫療和個人化診斷方法的投入，以提高診斷準確性和治療方案的發展。科學研究活動的活性化、有利的保險報銷政策以及生技公司與醫療機構之間合作的加強，都在加速創新。預防性醫療保健計畫的擴展進一步增加了對全面篩檢服務的需求。

隨著早期檢測成為全球癌症防治策略的關鍵要素，前景一片光明。人工智慧、數位病理學和基於生物標記的診斷技術的融合將提高篩檢的準確性和效率。開發中國家醫療基礎設施的擴建和癌症研究投入的增加將創造巨大的商業機會。診斷技術的持續創新將支持全球更有效、更便利的癌症篩檢。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球癌症檢測與篩檢市場：按類型分類

• 市場分析、洞察與預測
• 診斷
• 篩檢

第5章 全球癌症檢測與篩檢市場：依癌症類型分類

• 市場分析、洞察與預測
• 呼吸系統癌症
• 白血病
• 多發性骨髓瘤和淋巴瘤
• 皮膚癌
• 腹部和消化器官系統癌症
• 生殖器癌
• 口腔癌
• 泌尿器官系統癌症
• 內分泌癌
• 乳癌
• 其他

第6章：全球癌症檢測與篩檢市場：依方法分類

• 市場分析、洞察與預測
• 診斷影像
• 切片檢查
• 基因組和分子檢測（次世代定序、RT-PCR、微陣列、生物標記檢測等）

第7章 全球癌症檢測與篩檢市場：依產品類型分類

• 市場分析、洞察與預測
• 分子診斷
• 伴隨診斷

第8章 全球癌症檢測與篩檢市場：依階段分類

• 市場分析、洞察與預測
• 終末階段
• 階段 0-4
• 前景
• 其他疾病分期系統

第9章 全球癌症檢測與篩檢市場：依性別分類

• 市場分析、洞察與預測
• 男性
• 女士

第10章 全球癌症檢測與篩檢市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific
  • Illumina
  • Exact Sciences
  • Guardant Health
  • Hologic
  • Bio-Rad
  • Danaher
  • Agilent Technologies
  • Myriad Genetics
  • Invitae
  • Natera
  • Fujifilm
  • Olympus
  • Eiken Chemical
  • Labcorp

The global cancer testing screening market size is expected to reach USD 362.98 Billion in 2034 from USD 202.66 Billion in 2025, growing at a CAGR of 6.69 during 2026-2034.This market is witnessing robust growth as healthcare providers emphasize early disease detection to improve treatment outcomes and patient survival. Cancer testing and screening technologies enable timely identification of various cancers through imaging, laboratory diagnostics, molecular testing, and genetic analysis. Rising cancer prevalence, increasing public awareness, and expanding government screening initiatives are encouraging widespread adoption of advanced diagnostic solutions. Improvements in healthcare accessibility are also contributing to stronger market development.

Technological advancements in molecular diagnostics, liquid biopsy, genomic sequencing, and artificial intelligence-assisted imaging are transforming cancer detection capabilities. Healthcare organizations are investing in precision medicine and personalized diagnostic approaches to improve diagnostic accuracy and treatment planning. Growing research activities, supportive reimbursement policies, and increasing collaboration between biotechnology companies and healthcare institutions are accelerating innovation. Expansion of preventive healthcare programs continues to strengthen demand for comprehensive screening services.

The future outlook remains highly encouraging as early detection becomes an essential component of global cancer control strategies. Integration of artificial intelligence, digital pathology, and biomarker-based diagnostics will enhance screening accuracy and efficiency. Expanding healthcare infrastructure in developing economies and increasing investments in oncology research will create significant opportunities. Continuous innovation in diagnostic technologies will support more effective and accessible cancer screening worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Diagnostics
• Screening

By Cancer Type

• Respiratory System Cancer
• Leukemia
• Myeloma and Lymphoma
• Skin Cancer
• Abdominal/Digestive System Cancer
• Genital Cancer
• Oral Cancer
• Urinary System Cancer
• Endocrine System Cancer
• Breast Cancer
• Others

By Technique

• Imaging
• Biopsy
• Genomic and Molecular Tests (Next-Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others)

By Product Type

• Molecular Diagnostics
• Companion Diagnostics

By Stage

• Terminal
• Stage 0-4
• Prognosis
• Other Staging System

By Gender

• Male
• Female

COMPANIES PROFILED

• Thermo Fisher Scientific, Illumina, Exact Sciences, Guardant Health, Hologic, Bio-Rad, Danaher, Agilent Technologies, Myriad Genetics, Invitae, Natera, Fujifilm, Olympus, Eiken Chemical, Labcorp

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER TESTING SCREENING MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER TESTING SCREENING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Respiratory System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Myeloma and Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Abdominal/Digestive System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Genital Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Oral Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Urinary System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Endocrine System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER TESTING SCREENING MARKET: BY TECHNIQUE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technique
• 6.2. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Genomic and Molecular Tests (Next-Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER TESTING SCREENING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Product Type
• 7.2. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER TESTING SCREENING MARKET: BY STAGE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Stage
• 8.2. Terminal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Stage 0-4 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Prognosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Other Staging System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CANCER TESTING SCREENING MARKET: BY GENDER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Gender
• 9.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CANCER TESTING SCREENING MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Type
  • 10.2.2 By Cancer Type
  • 10.2.3 By Technique
  • 10.2.4 By Product Type
  • 10.2.5 By Stage
  • 10.2.6 By Gender
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Type
  • 10.3.2 By Cancer Type
  • 10.3.3 By Technique
  • 10.3.4 By Product Type
  • 10.3.5 By Stage
  • 10.3.6 By Gender
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Type
  • 10.4.2 By Cancer Type
  • 10.4.3 By Technique
  • 10.4.4 By Product Type
  • 10.4.5 By Stage
  • 10.4.6 By Gender
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Type
  • 10.5.2 By Cancer Type
  • 10.5.3 By Technique
  • 10.5.4 By Product Type
  • 10.5.5 By Stage
  • 10.5.6 By Gender
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Type
  • 10.6.2 By Cancer Type
  • 10.6.3 By Technique
  • 10.6.4 By Product Type
  • 10.6.5 By Stage
  • 10.6.6 By Gender
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL CANCER TESTING SCREENING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Thermo Fisher Scientific
  • 12.2.2 Illumina
  • 12.2.3 Exact Sciences
  • 12.2.4 Guardant Health
  • 12.2.5 Hologic
  • 12.2.6 Bio-Rad
  • 12.2.7 Danaher
  • 12.2.8 Agilent Technologies
  • 12.2.9 Myriad Genetics
  • 12.2.10 Invitae
  • 12.2.11 Natera
  • 12.2.12 Fujifilm
  • 12.2.13 Olympus
  • 12.2.14 Eiken Chemical
  • 12.2.15 Labcorp